Background
Phase 2, open-label study (CAPTIVATE) of fixed-duration ibrutinib + venetoclax (IVen) in treatment-naive CLL/SLL. Two cohorts: MRD cohort (N=164, MRD-guided randomization after 12 cycles IVen) and fixed-duration cohort (N=159, 3 cycles ibrutinib lead-in then 12 cycles IVen). Patients ≤70 years; IGHV status collected. CAPTIVATE established the rationale for all-oral fixed-duration ibrutinib + venetoclax in frontline CLL.
Interventions and follow up
Arm A (fixed duration): Ibrutinib 420 mg PO daily × 3 cycles, then ibrutinib + venetoclax (ramp-up to 400 mg) × 12 cycles
Arm B (MRD cohort): Ibrutinib + venetoclax × 12 cycles; uMRD patients then randomized to placebo vs ibrutinib maintenance
Primary endpoint: uMRD4 rate in peripheral blood after 12 cycles IVen (fixed-duration cohort); 1-year disease-free survival after randomization (MRD cohort)
Median follow-up: 31 months (fixed-duration cohort)
Arm B (MRD cohort): Ibrutinib + venetoclax × 12 cycles; uMRD patients then randomized to placebo vs ibrutinib maintenance
Primary endpoint: uMRD4 rate in peripheral blood after 12 cycles IVen (fixed-duration cohort); 1-year disease-free survival after randomization (MRD cohort)
Median follow-up: 31 months (fixed-duration cohort)
Results
uMRD4 (peripheral blood) after IVen: 56% (fixed-duration cohort)
uMRD4 (bone marrow): 46%
ORR: 97%
CR/CRi: 56%
MRD cohort 1-yr DFS (uMRD, placebo vs ibrutinib): 95% vs 100% — non-inferior
3-yr PFS (fixed-duration cohort): 88%
3-yr OS: 98%
uMRD4 (bone marrow): 46%
ORR: 97%
CR/CRi: 56%
MRD cohort 1-yr DFS (uMRD, placebo vs ibrutinib): 95% vs 100% — non-inferior
3-yr PFS (fixed-duration cohort): 88%
3-yr OS: 98%
Adverse events
Hematologic: Grade ≥3 neutropenia 35%
Cardiovascular: Atrial fibrillation any grade 14% (grade ≥3 6%), hypertension grade ≥3 14%, major hemorrhage 4%
Tumor lysis / GI: No clinical TLS; laboratory TLS 2%; diarrhea grade ≥3 5%
Discontinuation due to AEs: 14%
Cardiovascular: Atrial fibrillation any grade 14% (grade ≥3 6%), hypertension grade ≥3 14%, major hemorrhage 4%
Tumor lysis / GI: No clinical TLS; laboratory TLS 2%; diarrhea grade ≥3 5%
Discontinuation due to AEs: 14%
Conclusions
Fixed-duration ibrutinib + venetoclax (12 months) achieved high uMRD rates (56% in peripheral blood) and durable responses in treatment-naive CLL, with 88% 3-year PFS and 98% OS. MRD-guided randomization showed that uMRD-achieving patients did not require continued ibrutinib, supporting feasibility of chemotherapy-free fixed-duration therapy.
Key Limitations
Single-arm phase 2 design with no chemoimmunotherapy or BTKi-monotherapy comparator, limiting causal inference; cross-trial comparison only. Enrolled younger fit patients (≤70 years), limiting generalizability to older/unfit CLL (addressed by GLOW). The ibrutinib component carries cardiac toxicity (AFib 14%) absent from venetoclax-obinutuzumab regimens. Re-treatment efficacy at relapse and long-term durability beyond 3 years require longer follow-up. del(17p)/TP53 subgroup numbers small.
Clinical Context
CAPTIVATE, alongside GLOW, supported FDA approval of fixed-duration ibrutinib + venetoclax for treatment-naive CLL. It established the all-oral fixed-duration model as an alternative to venetoclax-obinutuzumab (CLL14). CLL17 subsequently showed VenI and VenO non-inferior to continuous ibrutinib. Zanubrutinib + venetoclax combinations are under investigation as next-generation alternatives with improved cardiac tolerability. ESMO-MCBS: not assigned.